RetinalGenix Reports $27K Cash, Going Concern Doubts, and Debt-for-Equity Swap
RTGN has more than doubled off its 52-week low of $0.25.
Summary
RetinalGenix's Q2 2026 10-Q shows cash of just $27,232 and substantial doubt about its ability to continue as a going concern. The company converted $996,007 of related-party debt into equity and disclosed a material weakness in internal controls.
Key Events · Earnings and Guidance · RTGN
-
Cash Position Critically Low
Cash of $27,232 as of June 30, 2026, up from $180 at March 31, 2026, but management states it funds operations for only a few days.
-
Going Concern Warning Reiterated
The company has an accumulated deficit of $18.8 million and liabilities of $2.67 million, with substantial doubt about its ability to continue as a going concern.
-
Debt-for-Equity Exchange with Sanovas
In August 2026, the company issued 442,670 shares at $2.25 per share to Sanovas to settle $996,007 of related-party debt, reducing liabilities but not providing cash.
-
New $50,000 Promissory Note
In July 2026, the company borrowed $50,000 from a shareholder at 6% interest, maturing October 1, 2026, providing a small cash infusion.
Analysis · RTGN · Industrial Applications And Services
RetinalGenix Technologies remains in a severe liquidity crisis with only $27,232 in cash as of June 30, 2026, against $2.67 million in liabilities. The company explicitly states it cannot fund operations beyond a few days without new capital. A subsequent debt-for-equity exchange with Sanovas converted $996,007 of debt into 442,670 shares at $2.25 per share, providing no cash but reducing liabilities. The filing also discloses a material weakness in internal controls and follows the resignation of the company's auditor in July 2026. The going concern warning, minimal cash, and reliance on related-party financing make this a critical update for investors.
At the time of this filing, RTGN was trading at $4.00 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $75M. The 52-week trading range was $0.25 to $20.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.